Australia's most trusted
source of pharma news
Posted 24 May 2022 PM
Just days after starting a study in the US of Vaxinia, Sydney-based Imugene is already looking to bring the cancer-killing virus treatment to Australia.
The Office of the Gene Technology Regulator today (Tuesday) received an application from global CRO Medpace to conduct a phase one study of Vaxinia in patients with solid cancers that are locally advanced or have spread throughout the body.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.